10-K: Mirion Technologies Reports Full Year 2023 Results, Showing Revenue Growth and Reduced Net Losses

Mirion Technologies, Inc., a global provider of radiation detection, measurement, analysis and monitoring solutions, announced its full-year 2023 financial results, highlighting an 11.6% increase in revenue and a significant reduction in net losses compared to the previous year.

Summary

• Mirion Technologies reported full-year 2023 revenues of $800.9 million, an 11.6% increase from $717.8 million in 2022.
• The Medical segment contributed $284.5 million in revenue, while the Technologies segment generated $516.4 million.
• The company reported a net loss of $98.7 million for 2023, a significant improvement from the $288.4 million net loss in 2022.
• The reduced net loss was attributed to increased revenues in both segments, decreased amortization expenses, lower selling, general, and administrative costs, and the absence of goodwill impairment charges that impacted the previous year.
• These positive factors were partially offset by increased interest expenses, a change in the loss from the fair value of warrant liabilities, and a loss on debt extinguishment.
• The company's backlog as of December 31, 2023, stood at $857.1 million, up from $737.4 million at the end of 2022.
• Mirion completed the acquisition of ec2 Software Solutions LLC and NUMA LLC for $33 million, expanding its software offerings in the medical segment.
• The company also sold its Biodex Rehab business for $1.0 million in cash and $7.0 million in deferred payments, although there are uncertainties regarding the collection of the deferred payments.
• Mirion continues to face challenges related to the global supply chain, inflation, and interest rates, but has implemented price increases and cost-saving measures to mitigate these impacts.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with revenue growth and reduced net losses, but is tempered by ongoing challenges and risks, resulting in a cautiously optimistic sentiment.

Positives

• Revenue growth of 11.6% year-over-year demonstrates strong demand for Mirion's products and services.
• Significant reduction in net loss indicates improved operational efficiency and cost management.
• Growth in both Medical and Technologies segments highlights the company's diversified revenue streams.
• Strategic acquisitions of ec2 and SIS expand Mirion's product portfolio and market reach.
• Strong backlog of $857.1 million provides visibility into future revenue.
• Debt reduction of $127 million strengthens the company's financial position.
• Implementation of cost-saving measures and price increases helps mitigate inflationary pressures.

Negatives

• The company still reported a net loss of $98.7 million in 2023, although it was a significant improvement from the previous year.
• The sale of the Biodex Rehab business resulted in a loss on disposal of $6.5 million.
• Uncertainty exists regarding the collection of $7.0 million in deferred payments from the sale of Biodex Rehab.
• The company faces ongoing challenges related to the global supply chain, inflation, and interest rates.
• The Russia-Ukraine conflict has impacted the company's business, particularly in the Technologies segment, and resulted in a goodwill impairment charge in 2022.
• A Russian customer has made claims against the company totaling $21 million related to project delays and a terminated contract, although Mirion disputes these claims.

Risks

• The ongoing Russia-Ukraine conflict and sanctions could further impact the company's business, particularly in the Technologies segment.
• The company faces risks associated with its reliance on sole or limited sources for certain materials and components.
• Supply chain disruptions and inflationary pressures could lead to production interruptions, delays, and increased costs.
• Fluctuations in foreign currency exchange rates could materially and adversely affect the company's financial results.
• Changes in government budgets and spending priorities, particularly in the defense and nuclear sectors, could impact demand for the company's products.
• The company is subject to extensive regulations, including those related to radiation safety, environmental protection, and medical devices, and non-compliance could result in penalties and legal expenses.
• The company faces risks related to legal claims and proceedings filed by or against it.
• The company's ability to compete and achieve future growth depends on its ability to protect its intellectual property and operate without infringing on the intellectual property of others.
• The company's indebtedness could adversely affect its financial condition and limit its ability to obtain additional financing.
• The company may require additional capital to support its growth plans, and such capital may not be available on acceptable terms.

Future Outlook

The company believes that significant opportunities for growth exist within each of its primary end markets, including medical, laboratories and research, nuclear, and defense. The company intends to continue pursuing organic growth by exploiting under-penetrated market opportunities, expanding its addressable market, developing new products and services, and continuously improving its cost structure and productivity. The company also plans to pursue strategic acquisitions and other transactions to complement its organic growth.

Management Comments

• Management disputes the claims made by the Russian customer related to project delays and the terminated contract and believes that the Company has substantial defenses.

Industry Context

Mirion's announcement aligns with broader industry trends, including the growing demand for radiation detection, measurement, and monitoring solutions in the medical, nuclear, defense, and research sectors. The increasing focus on nuclear energy as a clean energy source, coupled with the need for advanced radiation safety and security measures, positions Mirion to capitalize on these expanding markets. The company's focus on software and digital solutions also reflects the broader trend of digitalization in the healthcare and industrial sectors.

Comparison to Industry Standards

• Compared to Landauer (Fortive), Mirion's dosimetry services segment has a strong market position, particularly with its innovative Instadose product line.
• In the radiotherapy quality assurance market, Mirion competes with PTW, IBA, and Standard Imaging, and has gained market share through its comprehensive product line and focus on software solutions like SunCHECK.
• In the nuclear medicine market, Mirion's acquisition of Capintec and Biodex has strengthened its position against competitors like Comecer.
• In the nuclear energy market, Mirion's products and services are used throughout the entire nuclear fuel cycle, competing with companies like Thermo Fisher Scientific, Ortek (Ametek), Framatome, Fuji Electric, and Fluke (Fortive).
• In the defense market, Mirion's radiation detection and measurement solutions compete with those of FLIR (Teledyne) and Ludlum, particularly in areas like military CBRNE and security applications.
• Compared to industry standards, Mirion's revenue growth of 11.6% in 2023 is a positive indicator, especially considering the challenges posed by the global supply chain and inflation.
• The company's focus on software and digital solutions, as evidenced by its recent acquisitions, aligns with the broader industry trend of digitalization and automation.

Corporate Governance

Legal Proceedings

• The company is involved in a dispute with a Russian customer who has made claims totaling $21 million related to project delays and a terminated contract. The company disputes these claims and believes it has substantial defenses.
• A lawsuit was filed against the Company by a vendor alleging copyright infringement and breach of contract involving use of certain software licenses.

Related Party Transactions

• The Sponsor owned 18,750,000 shares of Class B common stock which automatically converted into 18,750,000 shares of Class A common stock at the closing of the Business Combination.
• The Sponsor purchased an aggregate of 8,500,000 private placement warrants.
• The Sponsor issued membership interests (Profits Interests) to certain Mirion employees and the current Chairman of the Board.
• The Company entered into a Subscription Agreement with GSAM Holdings LLC.
• The Sponsor agreed to loan the Company up to an aggregate of $2 million pursuant to the working capital note, which was forgiven in the Successor Period.
• An affiliate of the Sponsor was paid a portion of the underwriting commission from GSAH's IPO.
• The Company had agreements with Charterhouse Capital Partners LLP (CCP) for management fees and expenses related to secondary market offerings, but the agreement with CCP was terminated upon completion of the Business Combination.

Stakeholder Impact

• Shareholders: Potential dilution from the exercise of warrants and vesting of founder shares. Positive impact from revenue growth and reduced net losses.
• Employees: Potential impact from restructuring initiatives and changes in compensation structure. Focus on employee engagement, diversity, equity, and inclusion.
• Customers: Potential impact from supply chain disruptions and price increases. Benefits from new product and service offerings.
• Suppliers: Potential impact from supply chain disruptions and changes in procurement practices.
• Creditors: Debt reduction strengthens the company's financial position, but ongoing debt obligations and potential legal liabilities pose risks.

Next Steps

• The company plans to continue expanding into new geographic regions and pursuing customer outsourcing opportunities.
• Mirion intends to capitalize on the privatization of dosimetry services in regions outside the United States.
• The company will focus on developing new applications for existing technologies and introducing new products and services.
• Mirion will continue to improve its cost structure and productivity through ongoing operating improvements.
• The company will pursue strategic acquisitions and other transactions to complement its organic growth.

Key Dates

Keywords

radiation detection, radiation measurement, radiation monitoring, nuclear medicine, cancer treatment, dosimetry, radiotherapy, quality assurance, nuclear power, defense, homeland security, laboratories, research, industrial applications, imaging systems, spectroscopy, cybersecurity